Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 211 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 87% confidence The document is a CFO’s certification (Form 52-109FV2) attesting to review and fair presentation of the issuer’s interim financial report and MD&A for the period ended February 28, 2026. It is not the interim report itself, nor an announcement of its publication, but a required regulatory form under NI 52-109. It does not constitute the full interim/quarterly report (IR) and does not announce or link to the report; instead it is a standalone certification filing. This best fits the fallback “Regulatory Filings” category.
2026-04-24 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 75% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” under Canadian NI 52-109, signed by the CEO to certify the issuer’s interim financial report and interim MD&A. It is a regulatory certification form rather than the actual interim report or an announcement of report publication. There is no specific category for certification forms, so the correct classification is the general Regulatory Filings (RNS) fallback.
2026-04-24 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 72% confidence The document is titled FORM 52-109FV2 Certification of Interim Filings under Canadian NI 52-109. It is a CFO’s certification that the interim financial report and interim MD&A have been reviewed and fairly present the issuer’s condition. It does not contain the actual interim financial statements or MD&A text (so it is not the Interim/Quarterly Report itself) and is not announcing a report publication, dividend, or management change. It is a regulatory disclosure (a statutory certification) falling into the catch-all Regulatory Filings category.
2026-04-24 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 85% confidence The document is FORM 52-109FV2, a Certification of Interim Filings under NI 52-109 by the CEO, which is a regulatory compliance form accompanying interim financial statements and MD&A. It is not the interim report itself, nor an earnings release or other specific filing, so it falls under general regulatory filings.
2026-04-24 English
Interim MD&A - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing that Albany Graphite Corp., a subsidiary of Zentek, has engaged AppEco for a market study. It contains no financial results, no earnings data, no AGM materials, no change in management or board, no dividends, no financing, no proxy materials, and no legal or M&A actions. It is not an annual or interim report, nor an investor presentation or supplemental spreadsheet. It is a general corporate announcement and thus does not fit any of the more specific categories, falling into the fallback category of Regulatory Filings.
2026-04-24 French
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled “Management’s Discussion & Analysis for the three months ended February 28, 2026” and contains detailed management commentary on financial results, business trends, forward‐looking statements, and operational performance for the quarter. This is a standalone MD&A, fitting the definition of a Management Report (MDA) rather than a full interim report (IR) or mere announcement. Therefore, the correct classification is MDA.
2026-04-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.